EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Pharmacokinetics, mass balance, and metabolism of the novel potassium-competitive acid blocker JP-1366 in healthy Chinese adults following a single oral dose of [14C]JP-1366

Xuemei Liu, Decheng Deng, Jian Meng, Haitang Hu, Quankun Zhuang, Xue Zhou, Long Fu, Binke Fan, Xueting Xu, Qin Huang, Xiaoyan Chen, Fang Hou

Frontiers in Pharmacology · 10.11.2025 · 16

DOI: 10.3389/fphar.2025.1701581 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Frontiers in Pharmacology, online erschienen am 10.11.2025. Verfasst von Xuemei Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Clinical Research Center, Beijing GoBroad Hospital, Beijing, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

JP-1366 (zastaprazan), a novel potassium-competitive acid blocker (P-CAB), was approved in South Korea in 2024 for treating erosive gastroesophageal reflux disease (GERD). This mass balance study characterized the pharmacokinetics, metabolism, excretion, and safety profile of JP-1366 in humans, supporting its further clinical development in China.

Methods

Six healthy Chinese male adults received a single oral dose of 20 mg (100 μCi) [ 14 C]JP-1366 under fasting conditions in this open-label Phase I study. Serial samples of blood, plasma, urine, and feces were collected and analyzed to determine Pharmacokinetic parameters, total radioactive recovery, metabolic fate, and excretion routes.

Results

JP-1366 was rapidly absorbed, with median T max values of 0.875 h observed for both the parent drug and total radioactivity in human plasma. The mean plasma elimination half-life (t 1/2 ) was approximately 28 h for JP-1366-related material. Furthermore, the blood-to-plasma ratio of total radioactivity ranged from 0.561 to 0.645, indicating limited distribution of drug-related material into blood cells. Within 264 h post-dose, 94.3% of the administered radioactive dose was recovered through excretion, predominantly via feces (51.9%) and urine (42.4%). JP-1366 underwent extensive metabolism in vivo , generating 57 metabolites, while the parent drug remained undetectable in excreted samples. The principal metabolic pathways involved oxidations (Phase I) and the following glucuronidation (Phase I/II). JP-1366 exhibited a favorable safety profile, with no serious adverse events reported.

Conclusion

JP-1366 exhibited favorable pharmacokinetic properties characterized by rapid absorption, extensive metabolism, and predominant fecal excretion of drug-related material. The principal metabolic pathways involved oxidations and the following glucuronidation. Clinical Trial Registration http://www.chinadrugtrials.org.cn/ , identifier CTR20244931.

Schlagwörter

Stichwörter der Autor:innen

JP-1366P-CABsdrug metabolismmass balance studypharmacokineticsradioactivity

Autor:innen und Institutionen

  • Phase I Clinical Research Center, Beijing GoBroad Hospital, Beijing, China.
  • Livzon Pharmaceutical Group Co., Ltd., Zhuhai, China.
  • Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.

Zitieren

APA

Liu, X., Deng, D., Meng, J., Hu, H., Zhuang, Q., Zhou, X., Fu, L., Fan, B., Xu, X., Huang, Q., Chen, X., & Hou, F. (2025). Pharmacokinetics, mass balance, and metabolism of the novel potassium-competitive acid blocker JP-1366 in healthy Chinese adults following a single oral dose of [14C]JP-1366. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1701581

Vancouver

Liu X, Deng D, Meng J, Hu H, Zhuang Q, Zhou X, et al. Pharmacokinetics, mass balance, and metabolism of the novel potassium-competitive acid blocker JP-1366 in healthy Chinese adults following a single oral dose of [14C]JP-1366. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1701581

BibTeX
@article{Liu2025,
  author = {Liu, Xuemei and Deng, Decheng and Meng, Jian and Hu, Haitang and Zhuang, Quankun and Zhou, Xue and Fu, Long and Fan, Binke and Xu, Xueting and Huang, Qin and Chen, Xiaoyan and Hou, Fang},
  title = {Pharmacokinetics, mass balance, and metabolism of the novel potassium-competitive acid blocker JP-1366 in healthy Chinese adults following a single oral dose of [14C]JP-1366},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1701581}
}
Kostenlos starten →